Most authors currently recognize atrophic vascular poikiloderma as one of the variants of skin lymphoma - the poikiloderma form of mycosis fungoides. In some publications, this disease is classified as one of the variants of plaque parapsoriasis. The course of this disease is long, benign, with slow progression. The article presents a description of atrophic vascular poikiloderma in a young patient. At the time of treatment, the skin lesion had existed for about 4 years, the skin lesion was slowly progressing. Initially, the diagnoses were lichen sclerosus, lichen planus. A skin biopsy was performed with a histological examination, as a result of which a diagnosis of scleroatrophic lichen was established. In the future, the skin process progressed, rashes appeared that were not characteristic of scleroatrophic lichen. There was an assumption that the patient had vascular atrophic poikiloderma. The diagnosis was confirmed after performing histological and immunohistochemical studies of the skin biopsy. A feature of the case was the combination of two rare pathologies: rheumatic heart disease and vascular reticular poikiloderma. Establishing the diagnosis became possible only due to dynamic observation, repeated skin biopsy with histological and immunohistochemical studies
{"title":"Poikiloderma vascular atrophic in a young patient with a good clinical response to UV therapy","authors":"Nataliya Burtseva, Tatiana Vitalievna Melnikova, Konstantin Nirolaevith Monakhov, Evgeniy Vladislavovich Sokolovskiy","doi":"10.25208/vdv13277","DOIUrl":"https://doi.org/10.25208/vdv13277","url":null,"abstract":"Most authors currently recognize atrophic vascular poikiloderma as one of the variants of skin lymphoma - the poikiloderma form of mycosis fungoides. In some publications, this disease is classified as one of the variants of plaque parapsoriasis. The course of this disease is long, benign, with slow progression. The article presents a description of atrophic vascular poikiloderma in a young patient. At the time of treatment, the skin lesion had existed for about 4 years, the skin lesion was slowly progressing. Initially, the diagnoses were lichen sclerosus, lichen planus. A skin biopsy was performed with a histological examination, as a result of which a diagnosis of scleroatrophic lichen was established. In the future, the skin process progressed, rashes appeared that were not characteristic of scleroatrophic lichen. There was an assumption that the patient had vascular atrophic poikiloderma. The diagnosis was confirmed after performing histological and immunohistochemical studies of the skin biopsy. A feature of the case was the combination of two rare pathologies: rheumatic heart disease and vascular reticular poikiloderma. Establishing the diagnosis became possible only due to dynamic observation, repeated skin biopsy with histological and immunohistochemical studies","PeriodicalId":23618,"journal":{"name":"Vestnik dermatologii i venerologii","volume":"46 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139173182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pavel N. Trofimov, Khairutdinov R. Vladislav, Maria A. Fedotova, Irena E. Belousova
A case of idiopathic eruptive macular pigmentation in a child demonstrates a variant of skin hyperpigmentation of uncertain etiology. We described an 11-year-old boy with light brown spots in the torso and limbs that developed against the background of normal skin without an established provoking factor. On examination, it was found that the disease had developed within one year. Initially, the process was localized to the elbow folds and axillary areas, but later the rash spread to the trunk, neck and extremities. No inflammatory changes were observed at the base of the rash elements. The patient was examined for the presence of diseases that could underlie the skin manifestations, and histological examination was performed to verify the diagnosis. The established diagnosis of idiopathic eruptive macular pigmentation made it possible to choose a wait-and-see approach in treating the patient, due to the available literature data on the self-resolution of this pathology and ineffectiveness of the available dermatosis treatment options.
{"title":"Development of idiopathic eruptive macular pigmentation in an 11-year-old boy","authors":"Pavel N. Trofimov, Khairutdinov R. Vladislav, Maria A. Fedotova, Irena E. Belousova","doi":"10.25208/vdv11323","DOIUrl":"https://doi.org/10.25208/vdv11323","url":null,"abstract":"A case of idiopathic eruptive macular pigmentation in a child demonstrates a variant of skin hyperpigmentation of uncertain etiology. We described an 11-year-old boy with light brown spots in the torso and limbs that developed against the background of normal skin without an established provoking factor. On examination, it was found that the disease had developed within one year. Initially, the process was localized to the elbow folds and axillary areas, but later the rash spread to the trunk, neck and extremities. No inflammatory changes were observed at the base of the rash elements. The patient was examined for the presence of diseases that could underlie the skin manifestations, and histological examination was performed to verify the diagnosis. The established diagnosis of idiopathic eruptive macular pigmentation made it possible to choose a wait-and-see approach in treating the patient, due to the available literature data on the self-resolution of this pathology and ineffectiveness of the available dermatosis treatment options.","PeriodicalId":23618,"journal":{"name":"Vestnik dermatologii i venerologii","volume":"30 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138995577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Karamova, A. Kubanov, Ekaterina Vorotelyak, Olga Rogovaya, V. Chikin, Mariya A. Nefedova, E. Monchakovskaya
Background: inherited epidermolysis bullosa is a group of genetic skin disorders caused by mutations in genes encoding structural proteins of epidermis and dermo-epidermal junction. Clinical manifestations are characterized by spontaneous or trauma-induced skin and/or mucosal blistering, and extensive wounds. Cell therapy is considered to be a perspective therapeutic approach in improving wound healing process. Aims: to assess safety and efficacy of human skin equivalent in the treatment of inherited epidermolysis bullosa patients Materials and methods: 7 patients (5 female and 2 male subjects from the age of 20 to 55) with inherited epidermolysis bullosa with different clinical subtypes were enrolled in the study: 3 patients with intermediate recessive dystrophic epidermolysis bullosa, 2 patients with severe recessive dystrophic epidermolysis bullosa, 1 patient with dominant dystrophic epidermolysis bullosa and 1 patient with junctional epidermolysis bullosa. Transplantation of composite allogeneic living skin equivalent comprising allogeneic keratinocytes and fibroblasts in low concentration (5 mg/ml) embedded within a type I collagen gel matrix was performed. The living skin equivalent was developed at N.K. Koltsov Institute of Developmental Biology. 19 erosions and ulcers with a surface area between 0,4 cm2 and 120 cm2 were evaluated. At day 14 clinical assessment was performed. To assess level of expression immunofluorescence antigen mapping was used. Results: at day 14 complete erosion closure was achieved in 10 (53%) erosions. 4 (21%) erosions reduced in size 75%. Size reduction between 25% and 75% was shown in a single (5%) case. No clinical efficacy was demonstrated in 4 (21%) cases. Collagen VII expression increased comparing to baseline level and accompanied clinical improvement. Conclusions: the obtained data showed clinical efficacy of topical treatment with living skin equivalent, although no statistically significant difference was seen between living skin equivalent and atraumatic non-adhesive dressings. Keywords: inherited epidermolysis bullosa, junctional epidermolysis bullosa, recessive dystrophic epidermolysis bullosa, erosions, healing, topical treatment.
{"title":"Efficacy of human living skin equivalent in the treatment of inherited epidermolysis bullosa","authors":"A. Karamova, A. Kubanov, Ekaterina Vorotelyak, Olga Rogovaya, V. Chikin, Mariya A. Nefedova, E. Monchakovskaya","doi":"10.25208/vdv16249","DOIUrl":"https://doi.org/10.25208/vdv16249","url":null,"abstract":"Background: inherited epidermolysis bullosa is a group of genetic skin disorders caused by mutations in genes encoding structural proteins of epidermis and dermo-epidermal junction. Clinical manifestations are characterized by spontaneous or trauma-induced skin and/or mucosal blistering, and extensive wounds. Cell therapy is considered to be a perspective therapeutic approach in improving wound healing process. \u0000 Aims: to assess safety and efficacy of human skin equivalent in the treatment of inherited epidermolysis bullosa patients \u0000 Materials and methods: 7 patients (5 female and 2 male subjects from the age of 20 to 55) with inherited epidermolysis bullosa with different clinical subtypes were enrolled in the study: 3 patients with intermediate recessive dystrophic epidermolysis bullosa, 2 patients with severe recessive dystrophic epidermolysis bullosa, 1 patient with dominant dystrophic epidermolysis bullosa and 1 patient with junctional epidermolysis bullosa. Transplantation of composite allogeneic living skin equivalent comprising allogeneic keratinocytes and fibroblasts in low concentration (5 mg/ml) embedded within a type I collagen gel matrix was performed. The living skin equivalent was developed at N.K. Koltsov Institute of Developmental Biology. 19 erosions and ulcers with a surface area between 0,4 cm2 and 120 cm2 were evaluated. At day 14 clinical assessment was performed. To assess level of expression immunofluorescence antigen mapping was used. \u0000 Results: at day 14 complete erosion closure was achieved in 10 (53%) erosions. 4 (21%) erosions reduced in size 75%. Size reduction between 25% and 75% was shown in a single (5%) case. No clinical efficacy was demonstrated in 4 (21%) cases. Collagen VII expression increased comparing to baseline level and accompanied clinical improvement. \u0000 Conclusions: the obtained data showed clinical efficacy of topical treatment with living skin equivalent, although no statistically significant difference was seen between living skin equivalent and atraumatic non-adhesive dressings. \u0000 Keywords: inherited epidermolysis bullosa, junctional epidermolysis bullosa, recessive dystrophic epidermolysis bullosa, erosions, healing, topical treatment.","PeriodicalId":23618,"journal":{"name":"Vestnik dermatologii i venerologii","volume":"13 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138995136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PUVA therapy (photochemotherapy) has anti-inflammatory, immunosuppressive and antiproliferative effects, which makes it possible to use it for the treatment of patients with chronic inflammatory skin diseases, including atopic dermatitis. At the same time, there are no summarized data on the results of PUVA therapy in patients with atopic dermatitis. In this regard, the effectiveness and safety of PUVA therapy in patients with atopic dermatitis was evaluated according to the scientific literature. Literature search was carried out using the keywords "atopic dermatitis" "PUVA therapy", "photochemotherapy" in the databases of scientific publications PubMed and RSCI. The methods of irradiation used, as well as the effectiveness and safety of PUVA therapy in patients with atopic dermatitis were analyzed. 14 publications were found describing the results of 13 studies that evaluated the effectiveness of various methods of PUVA therapy in patients with atopic dermatitis - photochemotherapy with peroral use of a photosensitizer, photochemotherapy with its topical use, and PUVA baths. All studies have shown the effectiveness of PUVA therapy in patients with atopic dermatitis. Nevertheless, the limitations of using this method are noted the possibility of the development of adverse events caused by ultraviolet irradiation and taking a photosensitizer, which requires a careful assessment of the benefit-risk ratio for the patient when prescribing PUVA therapy to patients with atopic dermatitis. According to the available literature data, PUVA therapy should be prescribed to adult patients with severe atopic dermatitis who have had insufficiently effective other therapy.
{"title":"PUVA photochemotherapy for the patients with atopic dermatitis: a review","authors":"V. Chikin, A. Karamova","doi":"10.25208/vdv16093","DOIUrl":"https://doi.org/10.25208/vdv16093","url":null,"abstract":"PUVA therapy (photochemotherapy) has anti-inflammatory, immunosuppressive and antiproliferative effects, which makes it possible to use it for the treatment of patients with chronic inflammatory skin diseases, including atopic dermatitis. At the same time, there are no summarized data on the results of PUVA therapy in patients with atopic dermatitis. In this regard, the effectiveness and safety of PUVA therapy in patients with atopic dermatitis was evaluated according to the scientific literature. Literature search was carried out using the keywords \"atopic dermatitis\" \"PUVA therapy\", \"photochemotherapy\" in the databases of scientific publications PubMed and RSCI. The methods of irradiation used, as well as the effectiveness and safety of PUVA therapy in patients with atopic dermatitis were analyzed. 14 publications were found describing the results of 13 studies that evaluated the effectiveness of various methods of PUVA therapy in patients with atopic dermatitis - photochemotherapy with peroral use of a photosensitizer, photochemotherapy with its topical use, and PUVA baths. All studies have shown the effectiveness of PUVA therapy in patients with atopic dermatitis. Nevertheless, the limitations of using this method are noted the possibility of the development of adverse events caused by ultraviolet irradiation and taking a photosensitizer, which requires a careful assessment of the benefit-risk ratio for the patient when prescribing PUVA therapy to patients with atopic dermatitis. According to the available literature data, PUVA therapy should be prescribed to adult patients with severe atopic dermatitis who have had insufficiently effective other therapy.","PeriodicalId":23618,"journal":{"name":"Vestnik dermatologii i venerologii","volume":"130 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139174388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Andrey I. Bakulev, Olga Pritulo, Zhanna Kuntsevich, A. Khotko, Aastasia Yunovidova, Pavel Gorognichev, Oleg Ziganshin, Natalya Rudneva, Evgenya Bildyuk, Tatyana Repina, Valentina Dudko, Marya Maksimova
Rationale. Data from randomized clinical trials (RCTs) may differ from the results of the efficacy and safety of medicines in the conditions of daily work. Purpose: to obtain data on the long-term efficacy and safety of the use of the genetically engineered biological drug netakimab in real clinical practice. Methods. In everyday clinical practice, a multicenter non-interventional observational study BCD-085-NIS-01 (ORION) was conducted, which involved 260 adult patients with moderate to severe psoriasis. It has been shown that therapy with GIBA netakimab using a standard dose of 120 mg and a regimen in patients with psoriasis is effective for 104 weeks. Results. It was established that the survival rate of genetically engineered biological therapy of netakimab, when analyzing data of 104 weeks of observation, remains high both in bionaive patients and in persons who have previously received treatment for this dermatosis using monoclonal antibodies. The long-term safety profile of netakimab in real clinical practice is comparable to data previously obtained in RCTs and remains favorable for follow-ups up to 2 years. Keywords. Psoriasis; treatment; genetically engineered biological preparations; efficiency; safety
{"title":"Efficacy and safety of netakimab therapy in patients with moderate and severe psoriasis in real clinical practice","authors":"Andrey I. Bakulev, Olga Pritulo, Zhanna Kuntsevich, A. Khotko, Aastasia Yunovidova, Pavel Gorognichev, Oleg Ziganshin, Natalya Rudneva, Evgenya Bildyuk, Tatyana Repina, Valentina Dudko, Marya Maksimova","doi":"10.25208/vdv14864","DOIUrl":"https://doi.org/10.25208/vdv14864","url":null,"abstract":"Rationale. Data from randomized clinical trials (RCTs) may differ from the results of the efficacy and safety of medicines in the conditions of daily work. Purpose: to obtain data on the long-term efficacy and safety of the use of the genetically engineered biological drug netakimab in real clinical practice. Methods. In everyday clinical practice, a multicenter non-interventional observational study BCD-085-NIS-01 (ORION) was conducted, which involved 260 adult patients with moderate to severe psoriasis. It has been shown that therapy with GIBA netakimab using a standard dose of 120 mg and a regimen in patients with psoriasis is effective for 104 weeks. Results. It was established that the survival rate of genetically engineered biological therapy of netakimab, when analyzing data of 104 weeks of observation, remains high both in bionaive patients and in persons who have previously received treatment for this dermatosis using monoclonal antibodies. The long-term safety profile of netakimab in real clinical practice is comparable to data previously obtained in RCTs and remains favorable for follow-ups up to 2 years. Keywords. Psoriasis; treatment; genetically engineered biological preparations; efficiency; safety","PeriodicalId":23618,"journal":{"name":"Vestnik dermatologii i venerologii","volume":"42 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139267497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
O. G. Artamonova, A. Karamova, A. Kubanov, D. A. Verbenko, I. V. Kozlova
Background: Psoriatic arthritis is a chronic inflammatory disease of the joints, spine, and entheses that can occur in patients with psoriasis. The prevalence of psoriatic arthritis is 19.7%. In 70% of cases, psoriasis precedes the development of arthritis. It has been proven that a delay in the diagnosis of psoriatic arthritis even by 6 months is associated with a deterioration in long-term radiological and functional results, leading to disability. The problem of early diagnosis of joint damage can be solved by identifying predictors of the risk of developing psoriatic arthritis in patients with psoriasis. Aims: to determine possible predictors for the development of psoriatic arthritis in patients with psoriasis. Materials and methods: The open, uncontrolled, prospective study enrolled 250 patients. The main group consisted of 190 patients diagnosed with plaque psoriasis. The control group consisted of 60 patients with psoriatic arthritis. In order to identify associations of clinical and genetic (HLA-B27 carriage) parameters with the development of psoriatic arthritis, we compared the frequency of occurrence of these parameters in patients with psoriatic arthritis and without. Results: Among 190 patients with plaque psoriasis 128 (67.4%) men, 62 (32.6%) women, aged 18 to 84 years (40.3015.56), the average duration of psoriasis was 10.0911, 08 (0-57 years). Among 60 patients with psoriatic arthritis 39 (65%) men, 21 (35%) women aged 18 to 86 years (44.4314.15), the average duration of psoriasis was 20.4713.22 (2-57 years), the average duration of psoriatic arthritis was 7.979.95 (047 years). Сlinical predictors for the development of psoriatic arthritis in patients with psoriasis: nail psoriasis (OR=2.244 [95% CI: 1.245 - 4.045]), severe psoriasis (PASI20) (OR=2.148 [95% CI: 1.161 - 3.975), arterial hypertension (OR = 1.982 [95% CI: 1.031 - 3.812]), duration of psoriasis over 25 years (OR = 3.365 [95% CI: 1.676 - 6.756), р0,05 Conclusions: The joint consideration of informative predictors will allow us to develop an original multi-parameter mathematical model for calculating the risk of developing psoriatic arthritis in patients with psoriasis.
{"title":"Search for predictors of psoriatic arthritis in patients with psoriasis","authors":"O. G. Artamonova, A. Karamova, A. Kubanov, D. A. Verbenko, I. V. Kozlova","doi":"10.25208/vdv14871","DOIUrl":"https://doi.org/10.25208/vdv14871","url":null,"abstract":"Background: Psoriatic arthritis is a chronic inflammatory disease of the joints, spine, and entheses that can occur in patients with psoriasis. The prevalence of psoriatic arthritis is 19.7%. In 70% of cases, psoriasis precedes the development of arthritis. It has been proven that a delay in the diagnosis of psoriatic arthritis even by 6 months is associated with a deterioration in long-term radiological and functional results, leading to disability. The problem of early diagnosis of joint damage can be solved by identifying predictors of the risk of developing psoriatic arthritis in patients with psoriasis. Aims: to determine possible predictors for the development of psoriatic arthritis in patients with psoriasis. Materials and methods: The open, uncontrolled, prospective study enrolled 250 patients. The main group consisted of 190 patients diagnosed with plaque psoriasis. The control group consisted of 60 patients with psoriatic arthritis. In order to identify associations of clinical and genetic (HLA-B27 carriage) parameters with the development of psoriatic arthritis, we compared the frequency of occurrence of these parameters in patients with psoriatic arthritis and without. Results: Among 190 patients with plaque psoriasis 128 (67.4%) men, 62 (32.6%) women, aged 18 to 84 years (40.3015.56), the average duration of psoriasis was 10.0911, 08 (0-57 years). Among 60 patients with psoriatic arthritis 39 (65%) men, 21 (35%) women aged 18 to 86 years (44.4314.15), the average duration of psoriasis was 20.4713.22 (2-57 years), the average duration of psoriatic arthritis was 7.979.95 (047 years). Сlinical predictors for the development of psoriatic arthritis in patients with psoriasis: nail psoriasis (OR=2.244 [95% CI: 1.245 - 4.045]), severe psoriasis (PASI20) (OR=2.148 [95% CI: 1.161 - 3.975), arterial hypertension (OR = 1.982 [95% CI: 1.031 - 3.812]), duration of psoriasis over 25 years (OR = 3.365 [95% CI: 1.676 - 6.756), р0,05 Conclusions: The joint consideration of informative predictors will allow us to develop an original multi-parameter mathematical model for calculating the risk of developing psoriatic arthritis in patients with psoriasis.","PeriodicalId":23618,"journal":{"name":"Vestnik dermatologii i venerologii","volume":"146 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139269382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
V. Chikin, A. Kubanov, M. B. Zhilova, P. V. Gorodnichev, K. M. Aulova, A. Karamova
Background: Efficacy the narrow-band UVB phototherapy in patients with atopic dermatitis varies greatly. An important condition for achieving optimal therapeutic effect is the identification of factors that can impact on the efficacy of therapy and considering their influence when prescribing treatment. Objective: The present study aimed to identify the factors which affect the efficacy of narrow-band phototherapy in patients with atopic dermatitis Methods: A prospective, open-label trial was conducted to evaluate theefficacyandsafetyof narrow-band UVB phototherapy for patients with moderate-to-severe atopic dermatitis. All patients were treated with narrow-band UVB phototherapy four times weekly for 5 weeks. Disease severity was evaluated by SCORing of the Atopic Dermatitis Index (SCORAD) and Eczema Area and Severity Index (EASI). Distribution of patients by the severity of therapeutic effect was evaluated. To compare the efficacy of therapy depending on initial atopic dermatitis severity, initial and cumulative irradiation doses, skin phototype, and smoking status patients were divided into subgroups. Результаты: 40 patients with moderate-to-severe atopic dermatitis received course of narrow-band UVB phototherapy. After NB-UVB therapy SCORAD and EASI scores reduced from 45,611,4 at baseline to 22,612,4 (p0,05) and from 14,47,2 at baseline to 4,13,9 (p0,05) respectively demonstrating the efficacy of narrow-band UVB phototherapy in patients with atopic dermatitis. Our investigation showed that tobacco smokers had definitely lower efficacy of NB-UVB phototherapy in comparison with non-smokers. Narrow-band UVB phototherapy had definitely higher efficacy when it is started with an initial dose 0,20,3 J/cm2 chosen in compliance with results of MED determing in comparison with an initial dose 0,050,15 J/cm2 selected according to skin phototype. Заключение: Factors that impact on the efficacy of narrow-band UVB phototherapy in patients with atopic dermatitis were identified. It was determined that tobacco smoking is associated with lower therapeutic response to NB-UVB therapy and using higher initial dose is associated with higher efficacy of therapy.
{"title":"Narrow-band UVB phototherapy in patients with atopic dermatitis: analysis of the factors determining treatment efficacy.","authors":"V. Chikin, A. Kubanov, M. B. Zhilova, P. V. Gorodnichev, K. M. Aulova, A. Karamova","doi":"10.25208/vdv15828","DOIUrl":"https://doi.org/10.25208/vdv15828","url":null,"abstract":"Background: Efficacy the narrow-band UVB phototherapy in patients with atopic dermatitis varies greatly. An important condition for achieving optimal therapeutic effect is the identification of factors that can impact on the efficacy of therapy and considering their influence when prescribing treatment. Objective: The present study aimed to identify the factors which affect the efficacy of narrow-band phototherapy in patients with atopic dermatitis Methods: A prospective, open-label trial was conducted to evaluate theefficacyandsafetyof narrow-band UVB phototherapy for patients with moderate-to-severe atopic dermatitis. All patients were treated with narrow-band UVB phototherapy four times weekly for 5 weeks. Disease severity was evaluated by SCORing of the Atopic Dermatitis Index (SCORAD) and Eczema Area and Severity Index (EASI). Distribution of patients by the severity of therapeutic effect was evaluated. To compare the efficacy of therapy depending on initial atopic dermatitis severity, initial and cumulative irradiation doses, skin phototype, and smoking status patients were divided into subgroups. Результаты: 40 patients with moderate-to-severe atopic dermatitis received course of narrow-band UVB phototherapy. After NB-UVB therapy SCORAD and EASI scores reduced from 45,611,4 at baseline to 22,612,4 (p0,05) and from 14,47,2 at baseline to 4,13,9 (p0,05) respectively demonstrating the efficacy of narrow-band UVB phototherapy in patients with atopic dermatitis. Our investigation showed that tobacco smokers had definitely lower efficacy of NB-UVB phototherapy in comparison with non-smokers. Narrow-band UVB phototherapy had definitely higher efficacy when it is started with an initial dose 0,20,3 J/cm2 chosen in compliance with results of MED determing in comparison with an initial dose 0,050,15 J/cm2 selected according to skin phototype. Заключение: Factors that impact on the efficacy of narrow-band UVB phototherapy in patients with atopic dermatitis were identified. It was determined that tobacco smoking is associated with lower therapeutic response to NB-UVB therapy and using higher initial dose is associated with higher efficacy of therapy.","PeriodicalId":23618,"journal":{"name":"Vestnik dermatologii i venerologii","volume":"C-30 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139269863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Atopic dermatitis (AtD) is a chronic allergic skin disease, the most common of dermatoses during pregnancy. Exacerbation of AtD can be at any stage of pregnancy, its main causes are an increase in progesterone levels, the predominance of Th2 cytokines, psychoemotional stress, violations of the gastrointestinal tract. Changes occur in the clinical picture, the lesions on the face and extensor surfaces of the extremities, papules. Treatment options for pregnant women are limited due to the unethical nature of clinical trials. It is safe to use topical glucocorticosteroids, moisturizers, narrow-band UVB 311 nm, calcineurin inhibitors are relatively safe. In systemic therapy in severe cases, the use of cyclosporine or a short course of prednisone is recommended. It is possible to continue the course of azathioprine at a reduced dose. There is no evidence of the safety of selective immunosuppressants.
{"title":"Atopic dermatitis and pregnancy","authors":"S. Petrova, V. Albanova","doi":"10.25208/vdv13279","DOIUrl":"https://doi.org/10.25208/vdv13279","url":null,"abstract":"Atopic dermatitis (AtD) is a chronic allergic skin disease, the most common of dermatoses during pregnancy. Exacerbation of AtD can be at any stage of pregnancy, its main causes are an increase in progesterone levels, the predominance of Th2 cytokines, psychoemotional stress, violations of the gastrointestinal tract. Changes occur in the clinical picture, the lesions on the face and extensor surfaces of the extremities, papules. Treatment options for pregnant women are limited due to the unethical nature of clinical trials. It is safe to use topical glucocorticosteroids, moisturizers, narrow-band UVB 311 nm, calcineurin inhibitors are relatively safe. In systemic therapy in severe cases, the use of cyclosporine or a short course of prednisone is recommended. It is possible to continue the course of azathioprine at a reduced dose. There is no evidence of the safety of selective immunosuppressants.","PeriodicalId":23618,"journal":{"name":"Vestnik dermatologii i venerologii","volume":"4 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139266710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rifat R. Saytburkhanov, D. A. Verbenko, I. N. Kondrakhina, X. Plakhova, Ksenia M. Lagun, Аlexey A. Кubanov, E.V. Filonenko
Background: Basal cell carcinoma is the most widespread malignant skin neoplasm. Angiogenesis is critical for the growth and metastasis of malignant tumors. Aims: To study the levels of representation of transcripts in the foci of basal cell skin cancer before and after the therapy of genes for angiogenesis proteins and their receptors. Materials and methods: The study included 31 patients with confirmed basal cell skin cancer who received treatment, using a pulsed dye laser and long-pulsed neodymium laser. The patients provided skin punch biopsies from BCC lesions and after therapy from the same localization. The gene expression was analyzed with real-time reverse transcription PCR using endogeneous control, and the gene expression ration changes during the therapy were calculated according to Livaks double delta formulae. Results: An increased expression of the matrix metalloproteinase MMP9 and the tachykinin precursor TAC1 genes were revealed in skin biopsy samples of the superficial and nodular form of basal cell skin cancer during laser pulsed therapy. The expression of tumor necrosis factor TNF, epidermal growth factor receptor EGFR, fibroblast growth factor FGF2 genes increases to a lesser extent. It was shown that the expression of the calcitonin-related polypeptide alpha CALCA gene in the skin of patients is at basal level, which makes it possible to exclude the influence of the neuropeptide on the basal cell skin cancer pathogenesis. Conclusions: Among the factors of neoangiogenesis potentially influencing the development of basal cell skin cancer, the leading role of expression of the MMP9 matrix metalloproteinase and TAC1 precursor protein of tachykinin has been shown. Simultaneous changes in the level of these proteins may be due to neuroimmune interactions in the epidermis, which is probably realized by mast cells as the microenvironment of the basal cell carcinoma.
{"title":"Gene expression changes of angiogenesis factors during basal skin cancer laser treatment","authors":"Rifat R. Saytburkhanov, D. A. Verbenko, I. N. Kondrakhina, X. Plakhova, Ksenia M. Lagun, Аlexey A. Кubanov, E.V. Filonenko","doi":"10.25208/vdv14869","DOIUrl":"https://doi.org/10.25208/vdv14869","url":null,"abstract":"Background: Basal cell carcinoma is the most widespread malignant skin neoplasm. Angiogenesis is critical for the growth and metastasis of malignant tumors. Aims: To study the levels of representation of transcripts in the foci of basal cell skin cancer before and after the therapy of genes for angiogenesis proteins and their receptors. Materials and methods: The study included 31 patients with confirmed basal cell skin cancer who received treatment, using a pulsed dye laser and long-pulsed neodymium laser. The patients provided skin punch biopsies from BCC lesions and after therapy from the same localization. The gene expression was analyzed with real-time reverse transcription PCR using endogeneous control, and the gene expression ration changes during the therapy were calculated according to Livaks double delta formulae. Results: An increased expression of the matrix metalloproteinase MMP9 and the tachykinin precursor TAC1 genes were revealed in skin biopsy samples of the superficial and nodular form of basal cell skin cancer during laser pulsed therapy. The expression of tumor necrosis factor TNF, epidermal growth factor receptor EGFR, fibroblast growth factor FGF2 genes increases to a lesser extent. It was shown that the expression of the calcitonin-related polypeptide alpha CALCA gene in the skin of patients is at basal level, which makes it possible to exclude the influence of the neuropeptide on the basal cell skin cancer pathogenesis. Conclusions: Among the factors of neoangiogenesis potentially influencing the development of basal cell skin cancer, the leading role of expression of the MMP9 matrix metalloproteinase and TAC1 precursor protein of tachykinin has been shown. Simultaneous changes in the level of these proteins may be due to neuroimmune interactions in the epidermis, which is probably realized by mast cells as the microenvironment of the basal cell carcinoma.","PeriodicalId":23618,"journal":{"name":"Vestnik dermatologii i venerologii","volume":"52 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139268068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Atrophic scars are a common complication that accompanies the healing of vulgar acne. The condition is quite widespread among young people, and their physical and psychological consequences with improper treatment can persist throughout life. There are many therapies for atrophic scars, but limited efficacy and high frequency of side effects limit use of these methods. For optimal treatment of a patient's scar, it is necessary to predict with which treatment will prtovide the most satisfactory result in the short period of time with the minimum number of side effects. Analysis of numerous studies shows that there is no panacea for the treatment of atrophic scars, which explains the developing trend towards the development of combined treatment methods. The purpose of our review is to analyze injectable methods of therapy for atrophic scars with an emphasis on the latest achievements of the previous decade, since in recent years these methods have shown themselves not only as one of the most successful in therapy, but also, according to most authors, there is a huge potential to increase the efficacy of treatment in severe cases. Although, it is difficult to make an unbiased comparison of each therapy method due to the different sample sizes of studies, the strength of evidence, the specifics of therapy and other factors, nevertheless, there is a possibility of reaching consensus on which treatment methods are optimally suited for certain types of scars. This should be an absolute determining factor for choosing the best therapeutic strategy, whether it is monotherapy or combination therapy, in the treatment of atrophic scars with a minimum number of side effects.
{"title":"The possibilities of using injectables in the treatment of atrophic scars","authors":"Inessa Akopyan, Stanislav Murakov","doi":"10.25208/vdv3615","DOIUrl":"https://doi.org/10.25208/vdv3615","url":null,"abstract":"Atrophic scars are a common complication that accompanies the healing of vulgar acne. The condition is quite widespread among young people, and their physical and psychological consequences with improper treatment can persist throughout life. There are many therapies for atrophic scars, but limited efficacy and high frequency of side effects limit use of these methods. For optimal treatment of a patient's scar, it is necessary to predict with which treatment will prtovide the most satisfactory result in the short period of time with the minimum number of side effects. Analysis of numerous studies shows that there is no panacea for the treatment of atrophic scars, which explains the developing trend towards the development of combined treatment methods. The purpose of our review is to analyze injectable methods of therapy for atrophic scars with an emphasis on the latest achievements of the previous decade, since in recent years these methods have shown themselves not only as one of the most successful in therapy, but also, according to most authors, there is a huge potential to increase the efficacy of treatment in severe cases. Although, it is difficult to make an unbiased comparison of each therapy method due to the different sample sizes of studies, the strength of evidence, the specifics of therapy and other factors, nevertheless, there is a possibility of reaching consensus on which treatment methods are optimally suited for certain types of scars. This should be an absolute determining factor for choosing the best therapeutic strategy, whether it is monotherapy or combination therapy, in the treatment of atrophic scars with a minimum number of side effects.","PeriodicalId":23618,"journal":{"name":"Vestnik dermatologii i venerologii","volume":"82 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135112475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：